Navigation Links
New approaches may prevent certain side effects in BRAF mutation-positive melanoma
Date:11/13/2011

SAN FRANCISCO Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

The studies, presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011, further elucidated the potential mechanism of action underlying this skin lesion side effect, which could further the development of next-generation drugs with improved safety and efficacy profiles for the treatment of BRAF mutation-positive melanoma, according to the researchers.

"Our data suggest that adding an epidermal growth factor receptor (EGFR) inhibitor may prevent skin lesions that sometimes appear during treatment with a first-generation BRAF inhibitor," said Gideon Bollag, Ph.D., senior vice president of research at Plexxikon in Berkley, Calif. "Perhaps more importantly, our data also suggest that our next-generation BRAF inhibitors (which we call 'paradox breakers') represent a novel, single-agent treatment that may avoid this side effect and may also extend treatment durability."

In a laboratory study, Bollag and colleagues used skin cells activated by oncogenes such as HRAS or by signaling through the EGFR receptor with a first-generation BRAF inhibitor. They observed that treatment led to upregulation of ligands for the family of HER receptors, consequent skin cell transformation and enhanced growth. In contrast, Plexxikon's novel "paradox breakers" did not induce this upregulation and, therefore, may prevent the skin lesion side effect observed for all first-generation BRAF inhibitors to date.

Bollag said he and his research team were initially surprised by the upregulation of growth factor expression but were able to identify its cause with a model system. They then used this model system to differentiate the new "paradox breaker" compounds.

The "paradox breakers," which are in preclinical development, are being studied in BRAF-mutant cancer, and Plexxikon is aiming to file an investigational new drug application in 2012.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. LIAI launches new division to look at novel approaches to heart disease and inflammation
2. Genetic risk factors may tailor prostate cancer screening approaches
3. Experts discuss challenges in integrative approaches to science
4. MSU project may lead to new approaches against lung cancer
5. Swimming upstream: Molecular approaches to better understand male infertility
6. New paper examines approaches to measuring protein in foods in context of deadly adulterations
7. New approaches to skin cancer prevention
8. 2 in 1: Multi-tasking protein provides new approaches for anti-tuberculosis drugs
9. Project aims to fuse top-down, bottom-up approaches in systems biology
10. BUSM study identifies new potential approaches to treat myelofibrosis
11. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
(Date:3/3/2016)... Calif. , March 3, 2016  FlexTech, a ... the categories of Innovation, Research & Development, Leadership in ... Leadership. This is the 9 th year of ... group of companies and individuals from past years ... based on a pre-described set of criteria, by a ...
(Date:3/2/2016)... 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ... "Global Biometrics as a Service Market 2016-2020" ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the ... a Service Market 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... ... May 04, 2016 , ... Looking for a ... Diego’s premiere hands-on cooking experience. Offering everything from gourmet cooking classes to weekend ... won’t forget. , Guests that visit LaJollaCooks4u share an experience unlike any other. ...
(Date:5/4/2016)... , ... May 04, 2016 , ... PBI-Gordon Corporation is ... Agricultural Sales. , Doug began his career at PBI-Gordon in February 1988, after ... a wide variety of roles, ranging from customer service to national product manager, to ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs ... on May 31st and June 1st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/3/2016)... , May 3, 2016  Dr. Thomas ... surgeon in The Woodlands, Texas , ... 24 percent of treated fat cells in just 25-minutes, ... Close to 90 percent of Americans report feeling bothered ... Nonsurgical fat reduction procedures are a growing industry. This ...
Breaking Biology Technology: